SCHEMBL8514648

SCHEMBL8514648

NCCNc1cccc2cccc(S(=O)(=O)O)c12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 2/20 0.56
FABP4 P15090 1/20 0.56
CCNA2 P20248 1/20 0.56
CDK2 P24941 1/20 0.56
MAPK14 Q16539 1/20 0.56
NR4A1 P22736 1/20 0.55
CA12 O43570 3/20 0.49
CA9 Q16790 3/20 0.49
CA3 P07451 1/20 0.49
CA4 P22748 1/20 0.49
CA6 P23280 1/20 0.49
CA5A P35218 1/20 0.49
CA7 P43166 1/20 0.49
CA14 Q9ULX7 1/20 0.49
CA5B Q9Y2D0 1/20 0.49
ALDH1A1 P00352 2/20 0.47
HSD17B10 Q99714 2/20 0.47
TSHR P16473 1/20 0.47
RECQL P46063 1/20 0.47
HTR6 P50406 5/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30950399 1.00 TTR (0.56) TTRFABP4CCNA2CDK2MAPK14
SCHEMBL21857967 0.91 TTR (0.54) TTRFABP4CCNA2CDK2MAPK14
SCHEMBL30461559 0.84 CA12 (0.47) TTRFABP4CCNA2CDK2MAPK14
SCHEMBL29018091 0.84 CA12 (0.47) TTRFABP4CCNA2CDK2MAPK14
SCHEMBL21725437 0.83 TTR (0.60) TTRFABP4CCNA2CDK2MAPK14
SCHEMBL27459951 0.81 TTR (0.59) TTRFABP4CCNA2CDK2MAPK14
SCHEMBL6254 0.80 CA12 (0.54) TTRCA12CA9CA3CA4
SCHEMBL29349851 0.80 CA12 (0.54) TTRCA12CA9CA3CA4
SCHEMBL3384286 0.79 CA12 (0.53) TTRCA12CA9CA3CA4
SCHEMBL3384278 0.79 CA12 (0.53) TTRCA12CA9CA3CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11952328-B2 Selective ship inhibitors for treating disease THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2024-04-09 US claimed
US-20200277256-A1 SELECTIVE SHIP INHIBITORS FOR TREATING DISEASE THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK 2020-09-03 US claimed
WO-2020081852-A1 SELECTIVE SHIP INHIBITORS FOR TREATING DISEASE THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2020-04-23 WO claimed
CN-111051469-B Acid stabilization of quantum dot-resin concentrates and premixes 昭荣化学工业株式会社 2024-06-04 CN disclosed
US-11952328-B2 Selective ship inhibitors for treating disease THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2024-04-09 US disclosed
WO-2022018462-A1 CATECHOL BASED DERIVATIVES FOR USE IN THE PREVENTION OF DNA DAMAGE UNIVERSITY OF NEWCASTLE UPON TYNE (GB) 2022-01-27 WO disclosed
US-10961448-B2 Acid stabilization of quantum dot-resin concentrates and premixes NANOSYS, INC. (US) 2021-03-30 US disclosed
WO-2020236620-A1 METHODS FOR PREDICTING RESPONSIVENESS OF CANCER TO FERROPTOSIS-INDUCING THERAPIES MEMORIAL SLOAN KETTERING CANCER CENTER (US) 2020-11-26 WO disclosed
US-20200277256-A1 SELECTIVE SHIP INHIBITORS FOR TREATING DISEASE THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK 2020-09-03 US disclosed
US-20200277256-A1 SELECTIVE SHIP INHIBITORS FOR TREATING DISEASE THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK 2020-09-03 US disclosed
WO-2020081852-A1 SELECTIVE SHIP INHIBITORS FOR TREATING DISEASE THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2020-04-23 WO disclosed
CN-111051469-A Acid stabilization of quantum dot-resin concentrates and premixes 纳米系统公司 2020-04-21 CN disclosed
WO-2018226654-A1 ACID STABILIZATION OF QUANTUM DOT-RESIN CONCENTRATES AND PREMIXES SMITH AUSTIN (US) 2018-12-13 WO disclosed
US-20180345638-A1 ACID STABILIZATION OF QUANTUM DOT-RESIN CONCENTRATES AND PREMIXES NANOSYS, INC. (US) 2018-12-06 US disclosed
US-20170283733-A1 DISPERSANT VISCOSITY MODIFIERS WITH SULFONATE FUNCTIONALITY THE LUBRIZOL CORPORATION 2017-10-05 US disclosed
US-20170283733-A1 DISPERSANT VISCOSITY MODIFIERS WITH SULFONATE FUNCTIONALITY THE LUBRIZOL CORPORATION 2017-10-05 US disclosed
WO-2016044262-A1 DISPERSANT VISCOSITY MODIFIERS WITH SULFONATE FUNCTIONALITY THE LUBRIZOL CORPORATION (US) 2016-03-24 WO disclosed
WO-1999027921-A2 COMPOSITIONS AND METHODS FOR MODULATING THE ACTIVITY OF FIBROBLAST GROWTH FACTOR EISAI CO., LTD. (JP) 1999-06-10 WO disclosed
US-4841030-A Azo reactive dyestuffs BAYER AKTIENGESELLSCHAFT (DE) 1989-06-20 US disclosed
US-4089895-A COUPLER FOR AZO DYES BAYER AKTIENGESELLSCHAFT (DT) 1978-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200277256-A1 SELECTIVE SHIP INHIBITORS FOR TREATING DISEASE PPP5C, MTMR1, PPM1G TTR 1675/4885FABP4 1510/4885CCNA2 3763/4885
US-11952328-B2 Selective ship inhibitors for treating disease PPM1A, MTMR1, PPM1B TTR 2064/4885FABP4 854/4885CCNA2 4044/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.